Mosca, M., Arnaud, L., Askanase, A., Hobar, C., Becker, B., Singhal, S., Banerjee, S., Pomponi, S., Choi, J., & Strand, V. (2025). Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial. Lupus Science & Medicine, 12(1), e001517. https://doi.org/10.1136/lupus-2025-001517

Syphers, J. L., Wright, J. A., Liu, S., Gee, Y. S., Gao, F., Mudududdla, R., Che, D. Q., Chang, A., Sloan, E. K., Narasimhan, V., Heriot, A., Ramsay, R. G., de Nys, R., Silva, T. N., Vrbanac, L., Sammour, T., Lawrence, M. J., Tin, T., Maddern, G. J., … Baell, J. B. (2025). Discovery of WEE1 Kinase Inhibitors with Potent Activity against Patient-Derived, Metastatic Colorectal Cancer Organoids. Journal of Medicinal Chemistry, 68(8), 8065–8090. https://doi.org/10.1021/acs.jmedchem.4c02541

Brettell, S. B., Janha, O., Begen, A., Cann, G., Sharma, S., Olaniyan, N., Yelland, T., Hole, A. J., Alam, B., Mayville, E., Gillespie, R., Capper, M., Fidock, D. A., Milligan, G., Clarke, D. J., Tobin, A. B., & Jamieson, A. G. (2024). Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment. Journal of Medicinal Chemistry, 67(21), 18895–18910. https://doi.org/10.1021/acs.jmedchem.4c01300

Wierda, W. G., Shah, N. N., Cheah, C. Y., Lewis, D., Hoffmann, M. S., Coombs, C. C., Lamanna, N., Ma, S., Jagadeesh, D., Munir, T., Wang, Y., Eyre, T. A., Rhodes, J. M., McKinney, M., Lech-Maranda, E., Tam, C. S., Jurczak, W., Izutsu, K., Alencar, A. J., … Ghia, P. (2024). Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. The Lancet Haematology, 11(9), e682–e692. https://doi.org/10.1016/s2352-3026(24)00172-8

Payne, A. S., & Manfredo Vieira, S. (2024). Bruton’s Tyrosine Kinase Inhibition in Pemphigus: An Embattled Frontier. Journal of Investigative Dermatology, 144(8), 1667–1670. https://doi.org/10.1016/j.jid.2024.03.014

Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Maranda, E., Lamanna, N., Tam, C. S., Shah, N. N., Coombs, C. C., Ujjani, C. S., Fakhri, B., Cheah, C. Y., Patel, M. R., Alencar, A. J., Cohen, J. B., Gerson, J. N., … Jurczak, W. (2023). Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 389(1), 33–44. https://doi.org/10.1056/nejmoa2300696

Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez-Maffe, J., Zhu, X., Shirley, M. D., Ramkumar, T., Fessehatsion, A., Burks, H. E., Yerramilli-Rao, P., & Kapiteijn, E. (2023). A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. British Journal of Cancer, 128(6), 1040–1051. https://doi.org/10.1038/s41416-022-02133-6

Ford, M., Mauro, M., Aftandilian, C., Sakamoto, K. M., & Hijiya, N. (2022). Management of Chronic Myeloid Leukemia in Children and Young Adults. Current Hematologic Malignancy Reports, 17(5), 121–126. https://doi.org/10.1007/s11899-022-00673-5

Popmihajlov, Z., Sutherland, D. J., Horan, G. S., Ghosh, A., Lynch, D. A., Noble, P. W., Richeldi, L., Reiss, T. F., & Greenberg, S. (2022). CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Respiratory Research, 9(1), e001060. https://doi.org/10.1136/bmjresp-2021-001060